Splash Beverage Plans Merger with Medterra CBD to Enter $52M Cannabinoid Wellness Market
Splash Beverage Group signed a non-binding letter of intent to merge with Medterra CBD, which generated $52m revenue in fiscal 2025 and serves over two million customers. The deal would pivot Splash into a public cannabinoid wellness platform, with Medterra CEO JP Larsen set to join the board upon closing.
1. Proposed Merger Details
Splash Beverage Group has executed a non-binding letter of intent to merge with Medterra CBD, marking a strategic pivot from its beverage heritage into cannabinoid wellness. Financial terms remain undisclosed, and the companies have not indicated whether Splash will seek buyers for its existing drinks assets.
2. Medterra Financial Profile
Medterra CBD produces federally compliant cannabinoid wellness goods including gummies and tinctures, generating more than $52 million in revenue in fiscal 2025. The company serves over two million customers across the US and international markets.
3. Strategic Rationale and Regulatory Landscape
The merger is positioned as a transformative step to build a growth-oriented platform in cannabinoid wellness, regulated consumer health and scalable brand development. It aligns with recent federal policy shifts, including a December executive order on medical marijuana rescheduling and a CMS pilot initiative for CBD.
4. Leadership and Next Steps
Subject to transaction completion and regulatory approvals, Medterra CEO JP Larsen is expected to join Splash’s board and take on a senior operating role. The companies will participate in the CMS CBD pilot initiative and outline next steps for integrating their operations.